Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Documentation of high blood pressure measurements in the emergency department: factors associated with discussion and comparison to other settings.

Internal and emergency medicine·2026
Same author

Association of documented high blood pressure measurements with time to hypertension diagnosis.

The American journal of medicine·2025
Same author

Factors Associated With Discussing High Blood Pressure Readings in Clinical Notes.

American journal of hypertension·2024
Same author

A cluster randomized trial to evaluate a centralized remote clinical pharmacy service in large, health system primary care clinics.

Journal of the American College of Clinical Pharmacy : JACCP·2023
Same author

Effect of a Physician/Pharmacist Collaborative Care Model on Time in Target Range for Systolic Blood Pressure: Post Hoc Analysis of the CAPTION Trial.

Hypertension (Dallas, Tex. : 1979)·2021
Same author

Development of a centralized, remote clinical pharmacy service to enhance primary care.

Pharmacy practice·2021
Same journal

Visit-to-Visit Systolic Blood Pressure Variability Predicts Long-Term Cardiovascular Events After Coronary Artery Bypass Grafting.

Journal of clinical hypertension (Greenwich, Conn.)·2026
Same journal

Impact of Maternal Risk Stratification on Clinical Characteristics and Perinatal Outcomes in Singleton Pregnancies With Preeclampsia.

Journal of clinical hypertension (Greenwich, Conn.)·2026
Same journal

Antihypertensive Efficacy, Safety, and Adherence After Switching From a Free Combination of Bisoprolol/Metoprolol and Amlodipine to Bisoprolol/Amlodipine FDC Tablets (5/5 mg) in Chinese Patients With Hypertension.

Journal of clinical hypertension (Greenwich, Conn.)·2026
Same journal

Blood Pressure Variability in Acute Ischemic Stroke: Current Evidence, Measurement Challenges, and Future Directions.

Journal of clinical hypertension (Greenwich, Conn.)·2026
Same journal

Association of Triglyceride-Glucose Index, Triglyceride/HDL Cholesterol Ratio and Metabolic Score for Insulin Resistance With Asymptomatic Organ Damage in Previously Untreated Patients With Hypertension.

Journal of clinical hypertension (Greenwich, Conn.)·2026
Same journal

Letter to the Editor Regarding: "Associations of High-Sensitivity Cardiac Troponin and N-Terminal Pro-B-Type Natriuretic Peptide With Echocardiographic Features in Patients With Hypertension".

Journal of clinical hypertension (Greenwich, Conn.)·2026
See all related articles

Related Experiment Video

Updated: Jun 4, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Combination therapy in hypertension.

Alan H Gradman1, Jan N Basile, Barry L Carter

  • 1Western Pennsylvania Hospital, Pittsburgh, PA, USA. gradmanmd@aol.com

Journal of Clinical Hypertension (Greenwich, Conn.)
|March 4, 2011
PubMed
Summary
This summary is machine-generated.

Achieving blood pressure (BP) targets often requires combination therapy for hypertension. This position paper explores the rationale and strategies for effective BP management using drug combinations.

Related Experiment Videos

Last Updated: Jun 4, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Clinical Hypertension Management

Background:

  • Antihypertensive therapy aims to reduce cardiovascular risks without compromising quality of life.
  • Blood pressure reduction is the primary factor in mitigating cardiovascular events like stroke and heart failure.

Purpose of the Study:

  • To present a position paper on combination therapy for hypertension from the American Society of Hypertension.
  • To outline the scientific basis and pharmacologic rationale for combining antihypertensive drugs.
  • To review patient selection and discuss fixed-dose combinations.

Main Methods:

  • Review of existing data on combination therapy efficacy.
  • Analysis of pharmacologic principles for drug combinations.
  • Discussion of clinical trial implications for combination strategies.

Main Results:

  • Blood pressure (BP) reduction is key to cardiovascular risk reduction.
  • Approximately 75% of patients need combination therapy to reach BP goals.
  • Emphasis is increasing on practical methods for consistent BP control.

Conclusions:

  • Combination therapy is essential for achieving hypertension treatment goals in most patients.
  • Strategic drug selection and combination are crucial for effective cardiovascular risk management.
  • Understanding the benefits and drawbacks of fixed-dose combinations is important for clinical practice.